Skip to content
FDAMedicines

American Regent, Inc. Issues Voluntary Nationwide Recall of One Lot of Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL Due to the Presence of Visible Particulate Matter

FDA recall n-american-regent-inc-issues-voluntary-nationwide-recall-one-lot-papaverine-hydroc ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Products were found to contain particulate matter
Text from FDA, unedited.

The recalled product

July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass an
Text from FDA, unedited.

Company announcement, as FDA publishes it

July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass and/or paraformaldehyde.

Risk Statement: The administration of an injectable product containing particulate matter may result in local irritation or swelling. The particulate matter could travel through and block blood vessels in the heart, lungs or brain which can cause stroke and even lead to death. Patients with underlying cardiovascular or pulmonary compromise may be at increased risk. To date, American Regent, Inc. has not received any reports of adverse events related to this recall.

Papaverine is a prescription medication that relaxes smooth muscles and widens blood vessels, primarily used to treat visceral spasms, poor blood circulation, and erectile dysfunction. Papaverine Hydrochloride Injection, USP, is a clear, colorless pale-yellow solution and is available in a 2 mL single-dose vial containing 30 mg/mL

Papaverine Hydrochloride Injection, USP Lot # 25202 was distributed nationwide in the United States beginning September 30, 2025. NDC, lot, expiration date and distribution dates can be found on the table below.

Product Description: Papaverine Hydrochloride Injection, USP 60 mg/2 mL Single dose vial NDC: 0517-4002-25 Lot#: 25202 Expiration Date: 11/30/2026 Distribution Dates: 9/30/2025

American Regent, Inc. is notifying its distributors and customers by letter and is arranging for return/replacement etc. of all recalled products.

Distributors/retailers/healthcare facilities that have the product which is being recalled should stop using and return to place of purchase or discard the product.

Consumers and healthcare professionals with questions regarding this recall can contact American Regent Inc. using the below information. This product is an intravenous injection and is to be used by or under the direction of a physician. Patients that use this product which is being recalled should stop using them and contact their doctor or health care provider.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online: www.fda.gov/medwatch/report.htm

Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

American Regent, Inc. is committed to the safety of patients who rely on its products and is taking this precautionary action to protect public health.

Text from FDA (the company’s words), unedited.
  • American Regent, Inc. Papaverine Hydrochloride Injection, USP 60 mg/ 2 mL

Source

Issued by
U.S. Food and Drug Administration
Firm
American Regent, Inc.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Firm: American Regent, Inc., Medicine: Papaverine, Month: July 2026, Week 2026-W30. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Products were found to contain particulate matter”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

Which products are included?

FDA states: “July 24, 2026 – Shirley, NY, American Regent, Inc. is conducting a nationwide voluntary recall of a single lot of Papaverine Hydrochloride Injection, USP, 60 mg/2 mL single dose vial to the consumer level. The product is being recalled due to the presence of particulate matter identified as glass an”

When was this recall published?

FDA published this company announcement on July 24, 2026.

Other notices of American Regent, Inc.